| scholarly article | Q13442814 |
| P2093 | author name string | Douglas Yee | |
| Jeffrey S Miller | |||
| Elena G Chiorean | |||
| Virginia K Kohl | |||
| Juliette Gay | |||
| Tanya Repka | |||
| Katherine E Herwig | |||
| P433 | issue | 7 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | trastuzumab | Q412616 |
| metastatic breast cancer | Q12859063 | ||
| P304 | page(s) | 2440-2446 | |
| P577 | publication date | 2003-07-01 | |
| P1433 | published in | Clinical Cancer Research | Q332253 |
| P1476 | title | Trastuzumab and interleukin-2 in HER2-positive metastatic breast cancer: a pilot study | |
| P478 | volume | 9 |
| Q34376968 | A phase I trial of paclitaxel and trastuzumab in combination with interleukin-12 in patients with HER2/neu-expressing malignancies |
| Q34382125 | A phase II trial of trastuzumab in combination with low-dose interleukin-2 (IL-2) in patients (PTS) with metastatic breast cancer (MBC) who have previously failed trastuzumab |
| Q34344146 | Addition of GM-CSF to trastuzumab stabilises disease in trastuzumab-resistant HER2+ metastatic breast cancer patients |
| Q36060352 | Adjuvant cellular immunotherapy in patients with resected primary non-small cell lung cancer |
| Q43200269 | Administration of anti-HER2 antibody after nonmyeloablative allogeneic stem cell transplantation in metastatic breast cancer. |
| Q36245510 | Anti-erbB-2 antibody trastuzumab in the treatment of HER2-amplified breast cancer |
| Q34502870 | Anti-β₂M monoclonal antibodies kill myeloma cells via cell- and complement-mediated cytotoxicity |
| Q26852287 | Approaches to improve tumor accumulation and interactions between monoclonal antibodies and immune cells |
| Q92692992 | Biological Characterization of SB3, a Trastuzumab Biosimilar, and the Influence of Changes in Reference Product Characteristics on the Similarity Assessment |
| Q36460884 | Biological role of NK cells and immunotherapeutic approaches in breast cancer |
| Q90484961 | Clinical development of immunotherapies for HER2+ breast cancer: a review of HER2-directed monoclonal antibodies and beyond |
| Q38014085 | Combination strategies to enhance antitumor ADCC. |
| Q36702442 | Correlation between NK function and response to trastuzumab in metastatic breast cancer patients |
| Q31033214 | Determination of strongly overlapping signaling activity from microarray data. |
| Q49599148 | Harnessing the immune system in the battle against breast cancer |
| Q36671364 | IL-12 enhances the antitumor actions of trastuzumab via NK cell IFN-γ production |
| Q37709365 | IL-15 enhances the anti-tumor activity of trastuzumab against breast cancer cells but causes fatal side effects in humanized tumor mice (HTM). |
| Q33620124 | In vitro activity of pertuzumab in combination with trastuzumab in uterine serous papillary adenocarcinoma |
| Q47156322 | Interplay between Natural Killer Cells and Anti-HER2 Antibodies: Perspectives for Breast Cancer Immunotherapy. |
| Q36440214 | Molecular Mechanisms of Trastuzumab-Based Treatment in HER2-Overexpressing Breast Cancer |
| Q36586901 | Monoclonal antibody-based targeted therapy in breast cancer: current status and future directions |
| Q26797345 | NK Cell-Mediated Antibody-Dependent Cellular Cytotoxicity in Cancer Immunotherapy |
| Q37132866 | Potent in vitro and in vivo activity of an Fc-engineered humanized anti-HM1.24 antibody against multiple myeloma via augmented effector function |
| Q37355370 | Role of trastuzumab in the management of HER2-positive metastatic breast cancer. |
| Q35437978 | Synergistic innate and adaptive immune response to combination immunotherapy with anti-tumor antigen antibodies and extended serum half-life IL-2. |
| Q34766486 | Targeting the function of the HER2 oncogene in human cancer therapeutics |
| Q39290976 | Therapeutic antitumor efficacy of anti-epidermal growth factor receptor antibody, cetuximab, against malignant pleural mesothelioma |
| Q33644305 | Trastuzumab mediates antibody-dependent cell-mediated cytotoxicity and phagocytosis to the same extent in both adjuvant and metastatic HER2/neu breast cancer patients |
| Q36613598 | Trastuzumab-based treatment of HER2-positive breast cancer: an antibody-dependent cellular cytotoxicity mechanism? |
Search more.